CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...